154 related articles for article (PubMed ID: 37663730)
1. Recombinant anti-human epidermal growth factor receptor type 2 single-chain variable fragment-alpha-luffin fusion protein as a putative immunotoxin against human epidermal growth factor receptor type 2-positive breast cancer cells: an experimental research.
Damough S; Bayat E; Oghabi Bakhshaiesh T; Barkhordari F; Esmaeili R; Nematollahi L; Talebkhan Y
Ann Med Surg (Lond); 2023 Sep; 85(9):4348-4354. PubMed ID: 37663730
[TBL] [Abstract][Full Text] [Related]
2. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.
Park S; Nguyen MQ; Ta HKK; Nguyen MT; Lee G; Kim CJ; Jang YJ; Choe H
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204265
[TBL] [Abstract][Full Text] [Related]
3. A novel EGFR-specific recombinant ricin-panitumumab (scFv) immunotoxin against breast and colorectal cancer cell lines; in silico and in vitro analyses.
Naemi AA; Salmanian AH; Noormohammadi Z; Amani J
Eur J Pharmacol; 2023 Sep; 955():175894. PubMed ID: 37429519
[TBL] [Abstract][Full Text] [Related]
4. Design and construction of scFv-PE35KDEL as a novel immunotoxin against human epidermal growth factor receptor 2 for cancer therapy.
Shariaty Vaziri Z; Shafiee F; Akbari V
Biotechnol Lett; 2023 Apr; 45(4):537-550. PubMed ID: 36807722
[TBL] [Abstract][Full Text] [Related]
5. A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency.
Rezaie E; Amani J; Bidmeshki Pour A; Mahmoodzadeh Hosseini H
Eur J Pharmacol; 2020 Mar; 870():172912. PubMed ID: 31926992
[TBL] [Abstract][Full Text] [Related]
6. Crotamine-based recombinant immunotoxin targeting HER2 for enhanced cancer cell specificity and cytotoxicity.
Jang J; Nguyen MQ; Park S; Ryu D; Park H; Lee G; Kim CJ; Jang YJ; Choe H
Toxicon; 2023 Jul; 230():107157. PubMed ID: 37196787
[TBL] [Abstract][Full Text] [Related]
7. Cloning, expression and characterization of a HER2-alpha luffin fusion protein in
Barkhordari F; Sohrabi N; Davami F; Mahboudi F; Garoosi YT
Prep Biochem Biotechnol; 2019; 49(8):759-766. PubMed ID: 31032734
[TBL] [Abstract][Full Text] [Related]
8. Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
Xiang Y; Li Q; Huang D; Tang X; Wang L; Shi Y; Zhang W; Yang T; Xiao C; Wang J
Exp Biol Med (Maywood); 2015 Feb; 240(2):160-8. PubMed ID: 25125500
[TBL] [Abstract][Full Text] [Related]
9. Design and characterization of a recombinant immunotoxin for targeted therapy of breast cancer cells: In vitro and in silico analyses.
Barazesh M; Mohammadi S; Jalili S; Kavousipour S; Faraji SN; Mokarram P; Pirhadi S
Life Sci; 2021 Jan; 265():118866. PubMed ID: 33301810
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.
Zhou X; Qiu J; Wang Z; Huang N; Li X; Li Q; Zhang Y; Zhao C; Luo C; Zhang N; Teng X; Chen Z; Liu X; Yu X; Wu W; Wei YQ; Li J
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1081-90. PubMed ID: 22392077
[TBL] [Abstract][Full Text] [Related]
11. Manufacture and evaluation of a HER2-positive breast cancer immunotoxin 4D5Fv-PE25.
Peng Y; Wu Z; Pang Z; Zhang L; Song D; Liu F; Li Y; Lin T
Microb Cell Fact; 2023 May; 22(1):100. PubMed ID: 37198642
[TBL] [Abstract][Full Text] [Related]
12. [Targeted detecting HER2 expression with recombinant anti HER2 ScFv-GFP fusion antibody].
Gao G; Chen C; Yang Y; Yang H; Wang J; Zheng Y; Huang Q; Hu X
Sheng Wu Gong Cheng Xue Bao; 2012 Aug; 28(8):1002-14. PubMed ID: 23185900
[TBL] [Abstract][Full Text] [Related]
13. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin.
Dunn RD; Weston KM; Longhurst TJ; Lilley GG; Rivett DE; Hudson PJ; Raison RL
Immunotechnology; 1996 Sep; 2(3):229-40. PubMed ID: 9373315
[TBL] [Abstract][Full Text] [Related]
14. A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells.
Lee S; Park S; Nguyen MT; Lee E; Kim J; Baek S; Kim CJ; Jang YJ; Choe H
BMB Rep; 2019 Aug; 52(8):496-501. PubMed ID: 30670149
[TBL] [Abstract][Full Text] [Related]
15. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Hydra HALT-1 as a toxin moiety for recombinant immunotoxin.
Jiemy WF; Hiew LF; Sha HX; In LLA; Hwang JS
BMC Biotechnol; 2020 Jun; 20(1):31. PubMed ID: 32552895
[TBL] [Abstract][Full Text] [Related]
17. Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.
Simon N; Antignani A; Sarnovsky R; Hewitt SM; FitzGerald D
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27075852
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative and apoptotic effects of a specific anti-insulin-like growth factor I receptor single chain antibody on breast cancer cells.
Motallebnezhad M; Younesi V; Aghebati-Maleki L; Nickho H; Safarzadeh E; Ahmadi M; Movassaghpour AA; Hosseini A; Yousefi M
Tumour Biol; 2016 Nov; 37(11):14841-14850. PubMed ID: 27639384
[TBL] [Abstract][Full Text] [Related]
19. Construction and characterization of the recombinant immunotoxin RTA-4D5-KDEL targeting HER2/neu-positive cancer cells and locating the endoplasmic reticulum.
Jiao P; Zhang J; Dong Y; Wei D; Ren Y
Appl Microbiol Biotechnol; 2018 Nov; 102(22):9585-9594. PubMed ID: 30141083
[TBL] [Abstract][Full Text] [Related]
20. Design and construction of a recombinant lentiviral vector with specific tropism to human epidermal growth factor-overexpressed cancer cells: Developing a new retargeting system for lentivirus vectors.
Ebrahimabadi S; Shahbazi M; Akbari M; Golalipour M; Farazmandfar T
J Gene Med; 2019 Jun; 21(6):e3095. PubMed ID: 31050357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
